What is it about?
We explore the use of rilpivirine and dolutegravir in a cohort of treatment experienced HIV patients. Results about effectiveness, safety, and costs are provided.
Featured Image
Why is it important?
Evidence about the use of dolutegravir and rilpivirine as a salvage antiretroviral therapy in treatment-experienced patients is scarce.
Read the Original
This page is a summary of: Effectiveness, Safety, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients, Annals of Pharmacotherapy, August 2017, SAGE Publications,
DOI: 10.1177/1060028017728294.
You can read the full text:
Contributors
The following have contributed to this page
